Aspire Biopharma Warrant
ASBPW
33 hedge funds and large institutions have $4.47M invested in Aspire Biopharma Warrant in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 2 closing their positions.
735% more capital invested
Capital invested by funds: $536K → $4.47M (+$3.94M)
3% less funds holding
Funds holding: 34 → 33 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Crossingbridge Advisors
Pleasantville,
New York
|
+$6.12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$23.6K |
| 2 |
CCM
Context Capital Management
Lajolla,
California
|
-$5.27K |
| 3 |
EFI
EHP Funds Inc
Toronto,
Canada
|
-$753 |
| 4 |
CS
Clear Street
New York
|
-$4 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Walleye Trading
New York
| $1.18K | – | – | – |
|
27
Adage Capital Partners
Boston,
Massachusetts
| $1.05K | – | – | – |
|
|
MTCM
28
Mint Tower Capital Management
Amsterdam,
Netherlands
| $1K | – | – | – |
|
|
PMAM
29
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
MC
30
Meteora Capital
Boca Raton,
Florida
| $936 | – | – | – |
|
|
OAC
31
OMERS Administration Corp
Toronto,
Ontario, Canada
| $905 | – | – | – |
|
|
FPA
32
First Pacific Advisors
El Segundo,
California
| $783 | – | – | – |
|
|
PI
33
PEAK6 Investments
Chicago,
Illinois
| $375 | – | – | – |
|
|
CCM
34
Context Capital Management
Lajolla,
California
| – | -$5.27K | -175,000 | Closed |
|
|
EFI
35
EHP Funds Inc
Toronto,
Canada
| – | -$753 | -25,000 | Closed |
|
|
CA
36
Crossingbridge Advisors
Pleasantville,
New York
| – | +$6.12K | +166,667 | New |
|
ASBPW Hedge Fund Activity: Q2 2024 in Review
33 of the 6,927 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q2 2024, worth a combined $4.47M — up 735% from $536K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ASBPW and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.
The largest buyer was Crossingbridge Advisors, opening a new position worth an estimated $6.12K. The largest seller was Periscope Capital, cutting an estimated $23.6K.
- 33 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q2 2024, down from 34 in Q1 2024.
- Funds reported $4.47M of Aspire Biopharma Warrant stock for Q2 2024, up 735% quarter-over-quarter.
- 1 fund opened new Aspire Biopharma Warrant positions in Q2 2024 and 2 closed out, a net change of -1 holder.
- The largest Aspire Biopharma Warrant buyer in Q2 2024 was Crossingbridge Advisors, an estimated $6.12K added.
- The largest Aspire Biopharma Warrant seller in Q2 2024 was Periscope Capital, an estimated $23.6K sold.
Based on aggregated 13F filings for Q2 2024.